For the year ending 2025-12-31, CODX made $622,489 in revenue. -$47,314,379 in net income. Net profit margin of -7600.84%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue | 622,489 | 3,915,160 | ||
| Cost of revenue | 222,377 | 999,124 | ||
| Gross profit | 400,112 | 2,916,036 | ||
| Sales and marketing | 2,381,131 | 4,483,339 | ||
| General and administrative | 9,058,283 | 16,157,152 | ||
| Research and development | 19,137,242 | 20,979,589 | ||
| Depreciation and amortization | 1,106,808 | 1,377,266 | ||
| Impairment charges | 18,882,000 | - | ||
| Total operating expenses | 50,565,464 | 42,997,346 | ||
| Loss from operations | -50,165,352 | -40,081,310 | ||
| Interest income, net | 292,932 | 1,091,825 | ||
| Realized gain on investments | 683,365 | 870,745 | ||
| Gain (loss) on disposition of assets | -82,421 | 8,291 | ||
| Gain on remeasurement of acquisition contingencies | 805,863 | 714,876 | ||
| Loss on equity method investment in joint ventures | -46,301 | -186,067 | ||
| Total other income, net | 1,653,438 | 2,499,670 | ||
| Loss before income taxes | -48,511,914 | -37,581,640 | ||
| Income tax provision (benefit) | -1,615,978 | 57,368 | ||
| Net loss | -46,895,936 | -37,639,008 | ||
| Change in net unrealized gains (losses) on marketable securities, net of tax | -418,443 | 271,743 | ||
| Total other comprehensive income (loss) | -418,443 | 271,743 | ||
| Comprehensive loss | -47,314,379 | -37,367,265 | ||
| Basic EPS | -35.25 | -1.24 | ||
| Diluted EPS | -35.25 | -1.24 | ||
| Basic Average Shares | 1,330,200 | 30,335,350 | ||
| Diluted Average Shares | 1,330,200 | 30,335,350 | ||
Co-Diagnostics, Inc. (CODX)
Co-Diagnostics, Inc. (CODX)